Reading Time: 1 minute
Novartis is a European pharmaceutical heavyweight offering a compelling long-term investment story. This strength is underscored by the stock achieving a perfect score of 15 out of 15 points in our "Robustness Check." Following a recent period of consolidation, the stage may well be set for the trend to continue toward new highs. I view the scenario of a continuing uptrend as confirmed by the share price rise on September 1st, which followed a sharp jump in value. The key catalyst that day was Novartis’s presentation of highly convincing Phase...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
